All studies
Oncology · EHR · US
Merola 2024
Lung cancer
DAG reportedITT, PPSuperiorityAcademia, Industry3/5 disclosures
Comparisons
1
In the analysis
1
all comparisons pooled
Target trials
1
Emulations reported
1
2 treatments
Design and methods
- Estimand
- ITT, PP
- Design hypothesis
- Superiority
- Matching / weighting
- IPTW
- Analysis method
- Weighted marginal structural proportional hazards model, Weighted Kaplan-Meier estimator
- Missing data
- Multiple imputation
- Covariates adjusted
- 23
- DAG
- Yes
- QBA
- No
Data and sample
- Data type
- EHR
- Data sources
- 1
- Geography
- US
- Eligible sample
- 1854
- Treated
- 589
- Control
- 1265
- Emulations
- 1
- Treatments compared
- 2
Transparency
- Protocol
- https://clinicaltrials.gov/study/NCT05908799
- Preprint
- No preprint
- Data availability
- Unavailable
- Code availability
- Unavailable
- Conflicts of interest
- Declared: Industry, Government
- COI institutions
- Amgen, AbbVie, Bayer Pharmaceuticals, AstraZeneca, Gilead Sciences, Pfizer, Johnson & Johnson, UCB Pharma, Takeda, Boehringer Ingelheim, Veracity Healthcare Analytics, Exponent, MITRE, Greenwich LifeSciences
- Funding
- Declared: Private
- Funders
- Amgen, AbbVie, Bayer Pharmaceuticals, AstraZeneca, Gilead Sciences, Pfizer, and Johnson & Johnson
The 0-5 count records which disclosures are present. It is not a quality score: a data link does not establish that the data are reusable.
Provenance
- Review key
- 2024_Merola_LungCancer
- DOI
- https://dx.doi.org/10.1001/jamanetworkopen.2024.36535
- Affiliations
- Baylor College of Medicine, Duke-Margolis Center, Amgen, AbbVie, Bayer Pharmaceuticals, AstraZeneca, Gilead Sciences, Pfizer, Johnson & Johnson, COTA Healthcare, Tempus, ConcertAI, TriNetX, xCures, Loopback Analytics
- Sector
- Academia, Industry
- Target trials (study level)
- KEYNOTE-189
- Registration
- NCT02578680